Abbott Introduces the Next Generation of Influenza A and B and Strep A Assays with Fastest-Ever Time to Molecular Results

NEW ASSAYS EMPOWER CLINICIANS TO MORE QUICKLY MAKE THE RIGHT DIAGNOSIS AT THE POINT-OF-CARE AND PRESCRIBE THE RIGHT TREATMENT ABBOTT PARK, Ill., Oct. 25, 2018 -- (Healthcare Sales & Marketing Network) -- Abbott (NYSE: ABT) announced today that the U.S.... Diagnostics, FDA, Product Launch Abbott, Influenza, Streptococcus, ID NOW
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news